Treatment of mixed cryoglobulinemia: A rheumatology perspective

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Mixed cryoglobulinemia; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PEGINTERFERON; RIBAVIRIN; RITUXIMAB; ANTIVIRUS AGENT; STEROID;

ANTIVIRAL THERAPY; B CELL LYMPHOMA; CRYOGLOBULINEMIA; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULONEPHRITIS; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SERUM SICKNESS; SKIN ULCER; TREATMENT RESPONSE; VASCULITIS; ACUTE DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE CONTROL; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HEPATITIS C; NONHUMAN; PLASMA EXCHANGE;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CRYOGLOBULINEMIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT CARE TEAM; PLASMAPHERESIS; RHEUMATOLOGY; TREATMENT OUTCOME; VASCULITIS;

EID: 79960436581     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. MELTZER M, FRANKLIN EC: Cryoglobulinemia - a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40: 828-36.
2. FERRI C, GRECO F, LONGOMBARDO G et al.: Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 19: 621-4.
3. DE VITA S, DE RE V, GASPAROTTO D et al.: Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia. Arthritis Rheum 2000; 43: 94-102.
4. DE VITA S, SOLDANO F, ISOLA M et al.: Preliminary classification criteria for the cryoglobulinemic vasculitis. Ann Rheum Dis 2011 (in press).
5. DELLA ROSSA A, BALDINI C, TAVONI A, BOMBARDIERI S: How HCV has changed the approach to mixed cryoglobulinemia. Clin Exp Rheumatol; 27 (Suppl. 52): S115-23.
6. DE VITA S, QUARTUCCIO L, FABRIS M: Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune process, or both? Autoimmun Rev 2008; 8: 95-9.
7. CARSON D, CHEN PP, KIPPS TJ: New roles for rheumatoid factor. J Clin Invest 1991 ; 87: 379-83.
8. DE RE V, SANSONNO D, SIMULA MP et al.: HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006; 20: 1145-54.
9. PIETROGRANDE M, DE VITA S, ZIGNEGO A et al.: Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011. Epub Feb 14.
10. QUARTUCCIO L, PETRARCA A, MANSUTTI E et al.: Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010; 28 (Suppl. 57): 84-7.
11. TARANTINO A, CAMPISE M, BANFI G et al.: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
12. FERRI C, SEBASTIAN M, GIUGGIOLI D et al.: Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-74.
13. DE VITA S, QUARTUCCIO L, MASOLINI P et al.: A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome. Ann Rheum Dis 2010; 69 (Suppl. 3): 93.
14. FERRI C, SEBASTIANI M, CACOUB P et al.: Effects of rituximab in a large series of patients with HCV-associated mixed cryoglobulinemia syndrome. Ann Rheum Dis 2010; 69 (Suppl. 3): 234.
15. SAADOUN D, ROSENZWAJG M, LANDAU D, PIETTE JC, KLATZMANN D, CACOUB P: Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111: 5334-41.
16. QUARTUCCIO L, SALVIN S, FABRIS M, SACCO S, DE VITA S: Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 2008; 67: 1494-5.
17. PETRARCA A, RIGACCI L, CAINI P et al.: safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-42.
18. SENE D, GHILLANI-DALBIN P, AMOURA Z, MUSSET L, CACOUB P: Rituximab may form a complex with IgMk mixed cryoglobulin and induce severe sistemi reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60: 3848-55.
19. QUARTUCCIO L, DE MARCHI G, FABRIS M, DE VITA S: Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 2006; 4: 367-8.
20. SAADOUN D, RESCHE RIGON M et al.: Rituximab plus Peg-interferon-alpha/ ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.
21. DAMMACCO F, TUCCI FA, LAULETTA G et al.: Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-53.
22. GHANY MG, STRADER DB, THOMAS DL, SEEFF LB: Diagnosis, management, and treatment of hepatitis C: an update. American Association for the Study of Liver Diseases. Hepatology 2009; 49: 1335-74.
23. ZAJA F, RUSSO D, FUGA G, PATRIARCA F, ERMACORA A, BACCARANI M: Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999; 84: 1157-8.
24. ZAJA F, DE VITA S, MAZZARO C et al.: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.